Displaying drugs 11451 - 11475 of 12761 in total
Therapeutic allogeneic lymphocytes
Investigational
gp209-2M antigen
The gp209-2M antigen is derived from gp209, and has potential immunomodulatory and antineoplastic activities.
Investigational
ETBX-011
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational
Interleukin-15, human recombinant
Investigational
Odetiglucan
Investigational
Incomplete Freund's adjuvant
Investigational
Barecetamab
Investigational
BI-765063
BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).
Investigational
HPV-16 trojan peptide vaccine
HPV-16 trojan peptide vaccine is an investigational cancer immunotherapy consisting of a novel Trojan peptide complex, composed of human papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific CD4 and CD8 T cell responses.
Investigational
Vidutolimod
Vidutolimod is a Toll-like receptor 9 (TLR9) agonist. It is an investigational cancer vaccine.
Investigational
RO7502175
Investigational
UCPVax
Investigational
Sirexatamab
Investigational
GEN-001
Investigational
MRx0518
Investigational
XmAb24306
XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.
Investigational
ETBX-021
Investigational
ETBX-061
Investigational
GI-6301
Investigational
RO7300490
RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors).
Investigational
SynOV1.1
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Investigational
SYNB1891
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational
Ligufalimab
Ligufalimab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47. It is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With Myelodysplastic Syndrome).
Investigational
Displaying drugs 11451 - 11475 of 12761 in total